OncoMatch/Clinical Trials/NCT06933394
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Is NCT06933394 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Arsenic trioxide and MAPK inhibitors for neuroblastoma.
Treatment: Arsenic trioxide · MAPK inhibitors · Chemotherapy — This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Disease stage
Required: Stage INRG M, INSS STAGE 4
Metastatic disease required
Preoperative staging as INRG M stage or postoperative staging as INSS stage 4 (regardless of risk classification).
Demographics
Prior therapy
Cannot have received: chemotherapy and abdominal radiation therapy
Lab requirements
Kidney function
glomerular filtration rate (GFR) < 30 ml/(min·1.73 m²) or serum creatinine > 5 mg/dL (442 μmol/L) [excluded]
Liver function
aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 5× upper limit of normal (ULN), or serum total bilirubin ≥ 3× ULN [excluded]
Cardiac function
NYHA heart function class III or IV, or left ventricular ejection fraction (LVEF) < 50% [excluded]
Severe progressive or persistent heart failure: NYHA heart function class III or IV, or left ventricular ejection fraction (LVEF) < 50%. Severe progressive or persistent renal failure: glomerular filtration rate (GFR) < 30 ml/(min·1.73 m²) or serum creatinine > 5 mg/dL (442 μmol/L). Severe liver dysfunction: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 5× upper limit of normal (ULN), or serum total bilirubin ≥ 3× ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06933394 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy and abdominal radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage INRG M or INSS STAGE 4 is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages